Industry Update: Interim 503A and 503B Bulks Lists New Revisions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law